

## AMENDMENTS

### Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Presently amended) A composition comprising ~~intact cells, wherein said cells expression~~ major histocompatibility (MHC) antigens ~~with—representing~~ at least four common allotypes from a given mammalian species.
- 2-6. (Canceled)
7. (Presently amended) The composition of claim 1, wherein said antigens ~~are—comprise~~ both Class I and Class II antigens or other alloantigens coded by polymorphic genes.
8. (Presently amended) The composition of claim 1, wherein said ~~plurality is—composition~~ comprises MHC antigens representative of all known allotypes of said mammalian species.
9. (Original) The composition of claim 1, wherein said mammal is a human.
10. (Original) The composition of claim 9, wherein said allotypes include at least one of the following human allotypes:
11. (Presently amended/Withdrawn) The composition of claim 1, wherein said ~~cells—composition~~ further ~~expresses—comprises~~ an antigen from an enveloped virus.
12. (Original/Withdrawn) The composition of claim 11, wherein said virus is a herpesvirus.
13. (Presently amended/Withdrawn) The composition of claim ~~12~~11, wherein said virus is a retrovirus.
14. (Presently amended/Withdrawn) The composition of claim ~~[[1]]~~35, wherein said ~~intact cells—immunostimulatory compound~~ further ~~expresses—comprises~~ as cytokine.
15. (Original/Withdrawn) The composition of claim 14, wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-4, IL-7, IL-13,  $\gamma$ -interferon and GMCSF.

16. (Presently amended/Withdrawn) The composition of claim 1, wherein ~~intact cells~~said composition further ~~express~~comprises a costimulatory molecule.
17. (Original/Withdrawn) The composition of claim 16, wherein said costimulatory molecule is B7.
18. (Presently amended) The composition of claim ~~[[1]]~~33, wherein said cells are rendered incapable of growth.
19. (Original) The composition of claim 18, wherein said cells are lethally irradiated.
20. (Original) The composition of claim 1, further comprising a pharmaceutically acceptable carrier, diluent or excipient.
- 21-31. (Canceled)
32. (New) The composition of claim 1, wherein said MHC antigens are provided in a cell free form.
33. (New) The composition of claim 1, wherein said MHC antigens are provided in intact cells.
34. (New) The composition of claim 1, wherein said MHC antigens comprise synthetic peptides conjugated to a carrier molecule.
35. (New/Withdrawn) The composition of claim 1, wherein said composition further comprises an immunostimulatory compound.
36. (New/Withdrawn) The composition of claim 35, wherein said immunostimulatory compound is selected from the group consisting of BCG, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine, lipid A, MPL, RIBI, trehalose and dimycolate.